Heritable Human Genome Editing? It May Never Be Safe
By Katie Hasson,
Impact Ethics
| 12. 04. 2020
The “CRISPR babies” announced in headlines around the world recently turned two years old, and we still know nothing about their health or wellbeing. Debates continue about whether the societal risks of heritable genome editing are too great to proceed, as do calls for broadly inclusive public participation in such deliberations. In the meantime, we’ve been learning a lot about what can go wrong when using CRISPR to edit human embryos.
In October, the journal Cell published an article describing significant damage to human embryos edited with CRISPR. The experiments conducted in Dieter Egli’s lab at Columbia University found unintended rearrangements or deletions of large stretches of DNA at and around the targeted site. In some cases, the deletions were so large that an entire chromosome was lost. As one headline plainly put it: “In Embryos, Crispr Can Cut Out Whole Chromosomes—That’s Bad”.
The Cell article is the published version of a pre-print paper that, along with two others from Kathy Niakan’s and Shoukrat Mitalipov’s labs, received significant attention in June. At that time, Heidi Ledford...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...